Northeast Pharmaceutical Group (000597) Stock Overview

Northeast Pharmaceutical Group Co., Ltd. engages in the chemical raw materials, chemical preparations, pharmaceutical, pharmaceutical engineering, biomedicine, and other businesses in China. It offers vitamin products, including vitamin C, vitamin B1, vitamin B6, and levocarnitine series; anti-infection products, such as fosfomycin series, azithromycin series, berberine hydrochloride, chloramphenicol, and other products.; and reproductive system and sex hormone products comprising carprost, carboprost tromethamine, dapoxetine hydrochloride, and levonorgestrel and tadalafil tablets. The company also provides nervous system products, such as piracetam series, levetiracetam series, vinpocetine, and other products; essence and cannabis-containing series products, including morphine hydrochloride injection, pethidine hydrochloride injection, compound codeine phosphate syrup, morphine hydrochloride tablets, and oxycodone hydrochloride injection; anti-AIDS products comprising kedu/zidovudine tablets, efavirenz tablets, and other products; digestive system products, which include bacillus licheniformis, aluminum magnesium carbonate chewable tablets, and other products; and in vitro biological diagnostic reagent products, such as HIV, HBV, HCV, HPV, and TB molecular diagnostic reagents. In addition, it offers general health products, including chondroitin ammonia sulfate collagen D3 calcium capsules, protein powder, and probiotic powder; and other products, such as amlodipine maleate, narcotine syrup, xiaoke citridin tablets, acetaminophen tablets, qutong tablets, metronidazole tablets, tinidazole tablets, and amphenamine tablets. Further, the company provides obstetrics and gynecology system, urinary system, antiviral, cardiovascular and cerebrovascular, analgesic and analgesic, and biological diagnosis series medicines. Additionally, it engages in medical distribution business. The company was founded in 1946 and is based in Shenyang, China.